IN RE BRAND NAME PRESCRIPTION DRUGS ANTITRUST LIT., 94 C 897.

Decision Date04 January 1995
Docket NumberNo. 94 C 897.,94 C 897.
Citation878 F. Supp. 1078
PartiesIn re BRAND NAME PRESCRIPTION DRUGS ANTITRUST LITIGATION. This document relates to: All Cases.
CourtU.S. District Court — Northern District of Illinois

Greg Shinall, Sperling, Slater & Spitz, P.C., Chicago, IL, Jeff Robert Branick, Richard Lyle Coffman, Provost & Umphrey, Beaumont, TX, for Antitrust Litigation.

James M. McGraw, Looper, Reed, Mark & McGraw, Inc., Houston, TX, for Randalls Food & Drug.

Catherine A. Sazdanoff, Abbott Laboratories, Abbott Park, IL, Frank Cicero, Jr., James Andrew Langan, Jeffrey A. Leon, Anne J. McClain, Jeffrey S. Cashdan, Kirkland & Ellis, Chicago, IL, for Abbott Laboratories.

H. Blair White, John W. Treece, Bruce Michael Zessar, Sidley & Austin, Chicago, IL, for GD Searle & Co. defendant.

Kael Behan Kennedy, James L. Komie, Schuyler, Roche & Zwirner, Chicago, IL, Marguerite S. Boyd, John W. Nields, Jr., Howrey & Simon, Salvatore A. Romano, Patricia A. Gaegler, Arent, Fox, Kintner, Plotkin & Kahn, Washington, DC, for Bendley Western Industries, Inc.

Jerome H. Torshen, Torshen, Spreyer & Garmisa, Ltd., Lee A. Freeman, Freeman, Freeman & Salzman, P.C., Chicago, IL, David E. Everson, Stinson, Mag & Fizzell, P.C., Kansas City, MO, Michael Lee Brooks, Gregory D. Hanley, Brooks, Cahill & Hanley, Chicago, IL, Richard Alan Arnold, Scott E. Perwin, James J. Kenny, William J. Blechman, Kenny, Nachwalter, Seymour, Arnold, Critchlow & Spector, P.A., Miami, FL, Richard W. Giauque, Stephen T. Hard, Douglas H. Patton, Giauque, Crockett, Bendinger & Peterson, Salt Lake City, UT, Peter J. Venaglia, Jeffrey M. Strank, Dornbush, Mensch, Mandelstam & Schaeffer, New York City, for Marion Merrell Dow Inc.

Ruth F. Masters, Latham & Watkins, Ralph Joseph Gabric, Willian, Brinks, Olds, Hofer, Gilson & Lione, Ltd., Lee A. Freeman, Jr., John F. Kinney, James T. Malysiak, Freeman, Freeman & Salzman, P.C., Richard William Austin, Richard S. Wisner, Audrey A. Berish, Pretzel & Stouffer, Chtd., Thomas D. Rosenwein, Nancy Schaefer, David Stewart Fleming, Heather A. Libbey, Schaefer, Rosenwein & Fleming, Chicago, IL, Mark G. Arnold, Husch, Eppenberger, Donohue, Elson & Cornfeld, St. Louis, MO, George L. Saunders, Jr., Saunders & Monroe, Chicago, IL, William F. Cavanaugh, Jr., Patterson, Belknap, Webb & Tyler, Thomas F. Curnin, Laura Mezey, Cahill, Gordon & Reindel, New York City, Donald L. Flexner, Crowell & Moring, Jennifer A. Albert, Arent, Fox, Kintner, Plotkin & Kahn, Washington, DC, Richard J. Holwell, Ronald W. Davis, White & Case, New York City, Arthur Makadon, Mark S. Stewart, Leslie E. John, Daniel

Schoor-Rube, Stephen J. Kastenberg, Ballard, Spahr, Andrews & Ingersoll, Philadelphia, PA, Herbert Dym, David L. Meyer, Jonathan R. Galst, Covington & Burling, Washington, DC, Robert E. Davy, Robert E. Davy, Jr. & Associates, Chicago, IL, Frederick P. Furth, Furth, Fahrner & Mason, Joseph L. Alioto, Joseph L. Alioto Law Offices, San Francisco, CA, Barbara Reeves, Morrison & Foerster, Los Angeles, CA, John Alexander Cochrane, Cochrane & Bresnahan, Charles Harley Johnson, Johnson Law Office, Joseph Andrew Kowalcik, Kowalcik Law Office, St. Paul, MN, John Kenneth Kallman, Law Offices of John Kenneth Kallman, Chicago, IL, Robert A. Milne, Dewey Ballantine, New York City, for Burroughs Wellcome Co.

Craig Allen Varga, Peterson & Ross, Chicago, IL, Alan J. Weinschel, Bruce A. Colbath, Weil, Gotshal & Manges, New York City, Steven P. Mandell, Davidson, Goldstein, Mandell & Menkes, Chicago, IL, for Foxmeyer Drug Co.

William J. Gibbons, Latham & Watkins, Chicago, IL, J. Thomas Rosch, McCutchen, Doyle, Brown & Enersen, Trevor J. Chaplick, Latham & Watkins, San Francisco, CA, for McKesson Corp.

Jerome I. Chapman, Kenneth A. Letzler, Deena R. Bernstein, Jill T. Feeney, Arnold & Porter, Washington, DC, Kenneth M. Sullivan, Gardner, Carton & Douglas, Chicago, IL, for Glaxo, Inc.

Nathan P. Eimer, Sidley & Austin, Chicago, IL, Mary B. Cranston, Jeffrey S. Ross, Terrence A. Callan, San Francisco, CA, for Phone-Poulenc Rorer, Inc.

Thomas F. Gardner, Deborah Platt Herman, Jones, Day, Reavis & Pogue, Alan H. Silberman, Sanford Mark Pastroff, Evan G.S. Siegel, Sonnenschein, Nath & Rosenthal, Chicago, IL, David Klingsberg, Michael Malina, David Copeland, Kaye, Scholer, Fierman, Hays & Handler, New York City, for Pfizer Inc.

Daniel Richard Formeller, Andrea Ellen Kayne, Tressler, Soderstrom, Maloney & Priess, Donald E. Egan, Stephen David Libowsky, Katten, Muchin & Zavis, Chicago, IL, Kenneth R. Logan, Richard C. Weisberg, Joseph F. Tringali, Kathryn A. Clokey, Peter G. Koclanes, Simpson, Thacher & Bartlett, New York City, for American Home Products Corp.

Jacqueline A. Criswell, Tressler, Soderstrom, Maloney & Priess, Chicago, IL, Steven E. Bizar, Howard D. Scher, Stephen J. Levy, Montgomery, McCracken, Walker and Rhoads, Philadelphia, PA, for Alco Health Services Corp.

William M. Hannay, Linda K. Stevens, Schiff, Hardin & Waite, Chicago, IL, Robert K. Stanley, James H. Ham, III, Baker & Daniels, Indianapolis, IN, for Eli Lilly & Co.

Paul C. Saunders, Douglas D. Broadwater, Stephen S. Madsen, Cravath, Swaine & Moore, Kevin J. Arquit, Richard A. Cirillo, Rogers & Wells, New York City, Eric D. Freed, Law Offices of Eric D. Freed, Los Angeles, CA, for Bristol-Meyers Squibb Co.

Larry J. Saylor, Catherine M. Patterson, Miller, Canfield, Paddock & Stone, Detroit, MI, Martin J. Dubowsky, Martin J. Dubowsky, Ltd., Chicago, IL, James G. Vantine, Jr., B. Jay Yelton, III, Charles E. Ritter, Kalamazoo, MI, for Upjohn Co.

William F. Cavanaugh, Jr., Thomas W. Pippert, Roosevelt N. Nesmith, Patterson, Belknap, Webb & Tyler, New York City, for Johnson and Johnson Vision Products, Inc.

Michael M. Conway, Hopkins & Sutter, P.C., Scott M. Mendel, Michael Sennett, Matthew K. Phillips, Ellen Kornichuk Emery, Michael J. Abernathy, Stephen H. Wenc, Carolyn Suzanne Palk, Carolyn Suzanne Palk, Bell, Boyd & Lloyd, Chicago, IL, John W. Nields, Jr., Marguerite S. Boyd, Howrey & Simon, Washington, DC, Jennifer A. Albert, Arent, Fox, Kintner, Plotkin & Kahn, Washington, DC, for Purdue Frederick Co.

Aldo A. Badini, Deirdre M. McDonald, White & Case, Michael J. Gallagher, Dewey Ballantine, New York City, for Ciba-Geigy Corp.

William M. McErlean, Fredric Adam Cohen, Suzanne Robinson, Rudnick & Wolfe, Chicago, IL, for Thrift Drug Inc.

Michael M. Conway, Hopkins & Sutter, P.C., Chicago, IL, John W. Nields, Jr., Howrey & Simon, Washington, DC, for Schering-Plough Corp. Richard Lewis Reinish, Keck, Mahin & Cate, Chicago, IL, Arlin M. Adams, Schnader, Harrison, Segal & Lewis, Philadelphia, PA, Steve D. Shadowen, Schnader, Harrison, Segal & Lewis, Harrisburg, PA, Ira P. Tiger, Philadelphia, PA, for RX USA, Inc.

Stephen David Libowsky, Katten, Muchin & Zavis, Chicago, IL, Kenneth R. Logan, Joseph F. Tringali, Simpson, Thacher & Bartlett, New York City, for American Cyanamid Co.

MEMORANDUM OPINION

KOCORAS, District Judge:

This matter is before the court on the Manufacturer Defendants' motion for certification for interlocutory appeal. On October 18, 1994, this court issued an order denying the Manufacturer Defendant's motion for summary judgment. In that motion, the Manufacturer Defendants argued that the plaintiffs were indirect purchasers within the meaning of Illinois Brick Co. v. Illinois, 431 U.S. 720, 97 S.Ct. 2061, 52 L.Ed.2d 707 (1977). In denying the defendant's motion, we held that Illinois Brick had no application to cases involving allegations of vertical conspiracy and thus posed no bar to the plaintiffs' claims. Subsequent to the issuance of the October 18, 1994 Order, the Manufacturer Defendants moved to have the issue certified for interlocutory appeal. For the reasons set forth below, the defendant's motion is denied.

DISCUSSION

The Manufacturer Defendants seek to have the following issue certified for interlocutory appeal: In a private antitrust action under Section 1 of the Sherman Act, 15 U.S.C. § 1, and Section 4 of the Clayton Act, 15 U.S.C. § 15, involving an alleged conspiracy between and among manufacturer and wholesaler defendants, which results in higher manufacturer prices on goods purchased by wholesalers and resold to retailer plaintiffs, do Kansas v. UtiliCorp United, Inc., 497 U.S. 199, 110 S.Ct. 2807, 111 L.Ed.2d 169 (1990), and Illinois ex rel. Burris v. Panhandle E. Pipe Line Co., 935 F.2d 1469 (7th Cir.1991), cert. denied, 502 U.S. 1094, 112 S.Ct. 1169, 117 L.Ed.2d 415 (1992), bar retail purchasers from suing the manufacturers for damages based upon prices that were allegedly inflated at the manufacturer level?

As a general proposition, "permission to take an interlocutory appeal should be granted sparingly and with discrimination." In re Folding Carton Antitrust Litigation, 75 F.R.D. 727, 738 (N.D.Ill.1977). Certification is the exception and not the rule. Zygmuntowicz v. Hospitality Invs., 828 F.Supp. 346, 353 (E.D.Pa.1993). When deciding a motion for certification, the district court must consider the following factors: (1) whether the motion to be appealed involves a controlling question of law; (2) whether there is a substantial ground for difference of opinion on that question of law; and (3) whether an immediate appeal from the order may materially advance the ultimate termination of the litigation. 28 U.S.C. § 1292(b); Segni v. Commercial Office of Spain, 650 F.Supp. 1045, 1046 (N.D.Ill.1987). Although the issue to be appealed involves a controlling question of law, we find that the other two factors set forth in § 1292(b) have not been satisfied. As such, the defendant's motion for certification must be denied.

A. Substantial Grounds for Difference of Opinion

Interlocutory review "should not be used merely to provide review of difficult rulings in hard cases." McCann v. Communications Design Corp., 775 F.Supp. 1506, 1534 (D.Conn.1991) (citing United States Rubber Co. v. Wright, 359 F.2d 784, 785 (9th Cir.1966)). Rather, the existence...

To continue reading

Request your trial
19 cases
  • In re Lion Air Flight JT 610 Crash
    • United States
    • U.S. District Court — Northern District of Illinois
    • May 25, 2023
    ... ... be reversed. In re Brand Name Prescription Drugs ... Antitrust ... ...
  • Van Straaten v. Shell Oil Products Co.
    • United States
    • U.S. District Court — Northern District of Illinois
    • December 8, 2011
    ...a “substantial likelihood” exists that the district court's ruling will be reversed on appeal. In re Brand Name Prescription Drugs Antitrust Litigation, 878 F.Supp. 1078, 1081 (N.D.Ill.1995). The existence of conflicting authority may indicate that an issue is contestable. See Hoffman v. Ca......
  • U.S. Commodity Futures Trading Comm'n v. Kraft Foods Grp., Inc.
    • United States
    • U.S. District Court — Northern District of Illinois
    • July 19, 2016
    ...v. DISH Network L.L.C. , No. 12–CV–7350, 2014 WL 539746, at *5 (N.D.Ill. Feb. 11, 2014) (citing In re Brand Name Prescription Drugs Antitrust Litigation , 878 F.Supp. 1078, 1081 (N.D.Ill.1995) ). Defendants have not satisfied that test here.i. Question One As explained above, Defendants fir......
  • Jones v. B&J Rocket Am., Inc.
    • United States
    • U.S. District Court — Northern District of Indiana
    • May 17, 2016
    ...an immediate appeal under section 1292(b)." Id. "Certification is the exception and not the rule." In re Brand Name Prescription Drugs Antitrust Litig., 878 F.Supp. 1078, 1081 (N.D.Ill.1995).Id. at *2 (italics in original). It is clear then, and well-established, that district courts may en......
  • Request a trial to view additional results
2 books & journal articles
  • Robinson-Patman Act
    • United States
    • ABA Antitrust Library Antitrust Law Developments (Ninth Edition) - Volume I
    • February 2, 2022
    ...Corp. v. DIC Concrete Corp., 467 F. Supp. 1016, 1019-20 (S.D.N.Y. 1979); cf. In re Brand Name Prescription Drugs Antitrust Litig., 878 F. Supp. 1078, 1083 (N.D. Ill. 1995) (“Robinson-Patman Act claims are not subject to the indirect purchaser rule of Illinois Brick.”). 353. See, e.g., Natio......
  • Table of Cases
    • United States
    • ABA Antitrust Library Antitrust Law Developments (Ninth Edition) - Volume II
    • February 2, 2022
    ...Drugs Antitrust Litig., In re, 186 F.3d 781 (7th Cir. 1999), 1000, 1017 Brand Name Prescription Drugs Antitrust Litig., In re, 878 F. Supp. 1078 (N.D. Ill. 1995), 829 Brand Name Prescription Drugs Antitrust Litig., In re, 1994 U.S. Dist. LEXIS 16658 (N.D. Ill. 1994), 920 Brand Name Prescrip......

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT